Fleming AD, Mellor J, Jiang W, Storkey A, Styles CJ, McKeigue PM, Colhoun HM. Safe and efficient 2-year screening intervals allocated by manual and automated grading in nationwide diabetic retinopathy screening. Poster presented at the 58th EASD Annual Meeting; September 19, 2022. Stockholm, Sweden. [abstract] Diabetologia. 2022 Aug 3; 65(supplement 1):372. doi: 10.1007/s00125-022-05755-w
Mellor J, Jiang W, Fleming AD, Styles CJ, Storkey A, McKeigue PM, Colhoun HM, Scottish Diabetes Research Network. Evaluation of deep learning prediction models for cardiovascular risk prediction using fundus images from the Scottish Diabetic Retinopathy Screening programme. Poster presented at the 58th EASD Annual Meeting of the European Association for the Study of Diabetes; September 19, 2022. Stockholm, Sweden. [abstract] Diabetologia. 2022 Aug 3; 65(Supple 1):S408-9. doi: 10.1007/s00125-022-05755-w
Dong OM. Using the diffusion of innovation theory to understand the challenges and opportunities to advancing use of nutrigenetics in clinical practice. Lifestyle Genom. 2021 Dec;14(4):124-8. doi: 10.1159/000517760
Qi C, Musetti S, Fu LH, Zhu YJ, Huang L. Biomolecule-assisted green synthesis of nanostructured calcium phosphates and their biomedical applications. Chem Soc Rev. 2019 May 20;48(10):2698-737. doi: 10.1039/c8cs00489g
Zeisel SH, Niculescu MD, Meyer KA, Dong OM, Chmurzynska A, Kohlmeier M. Precision nutrition. A nutrigenetic-based framework to establish guidelines for choline intake. Presented at the 2019 Congress of the International Society of Nutrigenetics & Nutrigenomics; July 13, 2019. Cambridge, United Kingdom. [abstract] Lifestyle Genom. 2018; 11:178. doi: 10.1159/000501177
Dong OM. Pharmaconutrigenetics of antipsychotic-induced weight gain. Presented at the Congress of the International Society of Nutrigenetics & Nutrigenomics; July 12, 2019. Cambridge, UK. [abstract] Lifestyle Genom. 2018; 11.
Mollo A, Hernandez M, Marsal JR, Esquerda A, Rius F, Blanco-Vaca F, Verdaguer J, Pozzilli P, de Leiva A, Mauricio D, Action LADA 8. Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain. Diabetes Metab Res Rev. 2013 Sep;29(6):446-51. doi: 10.1002/dmrr.2411
Berria R, Rosenstock J, Silberman C, Davis KL, Horton ES. Weight loss and associated changes in glycaemic control and cardiovascular biomarkers in patients with type 2 diabetes mellitus receiving incretin therapies in a large cohort database. Poster presented at the 44th General Assembly of the European Association for the Study of Diabetes; September 2009. [abstract] Diabetologia. 2009 Sep; 52(Suppl. 1, Abst.755):S297.